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STRUCTURED ABSTRACT, KEYWORDS, HIGHLIGHTS, AND ACRONYMS 
 
On strategic choices faced by large pharmaceutical laboratories and 
their effect on innovation risk under fuzzy conditions 
 
Structured abstract 
Objectives. We develop a fuzzy evaluation model that provides managers at different 
responsibility levels in pharmaceutical laboratories with a rich picture of their innovation risk as 
well as that of competitors. This would help them take better strategic decisions around the 
management of their present and future portfolio of clinical trials in an uncertain environment. 
Through three structured fuzzy inference systems (FIS), the model evaluates the overall 
innovation risk of the laboratories by capturing the financial and pipeline sides of innovation risk.  
Methods and Materials. Three FIS, based on the Mamdani model, determine the level of 
innovation risk of large pharmaceutical laboratories according to the strategic choices they face. 
Two subsystems measure different aspects of innovation risk while the third one builds on the 
results of the previous two. In all of them, both the partitions of the variables and the rules of the 
knowledge base were agreed through an innovative 2-tuple-based method. With the aid of experts, 
we have embedded knowledge into the FIS and validated the model.  
Results. In an empirical application of the proposed methodology, we evaluate a sample of 31 
large pharmaceutical laboratories in the period 2008-2013. Depending on the relative weight of 
the two subsystems in the first layer (capturing the financial and the pipeline sides of innovation 
risk), we estimate the overall risk. Comparisons across laboratories are made and graphical 
surfaces are analyzed in order to interpret the results. We have also run regressions to better 
understand the implications of our results.  
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Conclusions. The main contribution of this work is the development of an innovative fuzzy 
evaluation model that is useful for analyzing the innovation risk characteristics of large 
pharmaceutical laboratories given their strategic choices. The methodology is valid for carrying 
out a systematic analysis of the potential for developing new drugs over time and in a stable 
manner while managing the risks involved. We provide all the necessary tools and datasets to 
facilitate the replication of the system, which may be easily applied to other settings.  
Keywords 
Fuzzy inference systems; 2-tuple-based method; innovation risk; R&D; Pharmaceutical 
laboratories 
Highlights  
- Consensual fuzzy sets and rules are used to model innovation risk in large pharmaceutical 
laboratories, clarifying the system for pharmaceutical decision-makers and stakeholders. 
- With the aid of experts, we have combined knowledge with large and diverse datasets 
and embedded it into the fuzzy inference systems. 
- The fuzzy evaluation model captures both the financial side and the pipeline side of 
innovation risk of pharmaceutical companies operating in uncertain environments. 
- The fuzzy evaluation model we develop in this work has been applied to evaluate 
innovation risk in a sample of 31 large pharmaceutical laboratories covering the period 
from 2008 to 2013. 
Acronyms 
ATC  Anatomical, Therapeutic, Chemical (classification system) 
CFO  Chief Financial Officer 
CIO  Chief Innovation Officer 
CTs  Clinical trials 
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CTs x Prob Probabilities of success per ATC from the corresponding phase (I, II, III and IV) 
of each CT to approval per pharmaceutical laboratory  
EMA  European Medicines Agency 
FDA  Food and Drug Administration 
FIS  Fuzzy Inference System 
NCEs  New Chemical Entities 
NCEs x Prob Probabilities of success per ATC from Phase I to Approval of New Chemical 
Entities 
NFTs  Number of financial transactions 
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MANUSCRIPT 
 
On strategic choices faced by large pharmaceutical laboratories and their 
effect on innovation risk under fuzzy conditions 
 
1. Introduction  
New clinical trial strategies are being proposed, focused on reducing timelines, optimising clinical 
development plans, and assessing and managing risks. However, many of those strategies are 
implemented on an individual trial basis, without considering a fully integrated global development 
plan. In light of this, a systemic framework for global clinical development analysis and optimization is 
required (see e.g. Chang et al., 2019). 
Given that 70 to 90% of the costs of developing new medicines can be associated with clinical trials 
(Matsushita et al., 2019), enhancing decision making around the portfolio of critical trials can be 
expected to result in huge improvements in the healthcare industry. Harrison (2016) studies the reasons 
for clinical failure based on the reported causes of drug attrition by clinical development. As may be 
anticipated, the bulk of failures were associated with lack of efficacy (52%) and lack of safety (24%). 
However, as may not be anticipated, in third place, failures in strategy (15%) appears to be a key factor 
in clinical trial failure. 
Strategic decision making in clinical trials is a hot topic given the need for new and more efficient types 
of clinical trial designs. The pharmaceutical industry requires de implementation of new strategic 
approaches to innovative clinical trials design and management of candidate drugs with more potential 
for success (Janiaud et al.  2019; Verweij et al., 2019). These three examples focus on improving clinical 
trials targeted at a single disease area (oncology in these three cases). Tucker et al. (2017) propose a new 
model that integrates information about clinical trials targeted at degenerative diseases such as cancer. 
They claim that clinical trials are usually conducted over a population within a specific period in order 
to study certain characteristics of a single health issue or a single disease process. They propose a 
calibrated model that integrates different sources of incomplete information (cross-section info not 
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directly related to longitudinal info) in order obtain a better picture in the dynamics of degenerative 
diseases.  
We propose a fuzzy model that captures innovation risk across all the different disease areas to obtain a 
global picture of innovation risk in a given lab. Prior fuzzy works have shown several applications of 
fuzzy methodologies in the medical and pharmaceutical industries. Some researchers use this approach 
to improve medical procedures and training at hospitals, such as Mendez et al. (2018) and Nakawala et 
al. (2018). From a different prism, Gascón et al. (2007) classify countries depending on their likelihood 
to consume and produce generics through fuzzy techniques.  
Other contributions of fuzzy logic to the healthcare sector focus on strategic decision making at 
pharmaceutical firms, see e.g. Puente et al. (2011). This prior study takes into consideration that risk 
issues are key in the pharmaceutical generic industry, often deterring managers from expanding in this 
business. However, the pipeline management of pharmaceutical companies that only produce generics, 
without investing in significant R&D, is comparatively simpler. In this article, we develop an innovative 
fuzzy evaluation model aimed at assessing innovation risk in the pharmaceutical industry. This fuzzy 
model is designed to help managers at R&D-intensive laboratories take strategic decisions around their 
portfolio of new drugs. With the aid of experts in Biochemistry, the pharmaceutical industry, and value 
creation, we have embedded knowledge into and calibrated the FIS and we have validated the operation 
of the resulting evaluation model. 
From this perspective, the contribution of our article is aligned with that by Guo et al. (2018), who 
construct a model for selecting a portfolio of R&D projects under uncertainty. Their proposal, who takes 
simultaneously into account strategic issues and financial issues, combines fuzzy techniques with the 
real options approach. They transform the fuzzy model into a binary linear programming problem, 
calculating the Pareto frontier than optimizes the proposed multi-objective function. As we do in this 
work, Guo et al. (2018) consider risk constraints, resource constraints and technological constraints. 
They apply the model to a single, relatively small, Chinese pharmaceutical company, which is named 
as “Company X”. Nothing is known about this laboratory, apart from the fact that it was founded in 
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1994 and started a project scheme in 2002. Every year this company selects a specific number of projects 
(around 30) to implement from a set of 100 candidate projects. 
In our case, we develop an innovative fuzzy evaluation model to analyze innovation risk in a set of large, 
multinational pharmaceutical companies. In the application of the system we propose, we use only 
publicly available data from up-to-date datasets of different nature. The fuzzy model combines different 
information sources to produce the innovation risk outcome, capturing both the financial and pipeline 
sides of innovation risk that will help managers at R&D intensive pharmaceutical laboratories in their 
strategic decision-making processes on how to configure their global portfolio of clinical trials. In this 
sense, the system enables managers to compare the innovation risk of their laboratories with that of 
competitors, allowing them to visualize simultaneously different perspectives of innovation risk.  
The appendices offer more information on the public information datasets that we have used, while the 
online appendix provides the relevant files associated with our proposed fuzzy model. In light of this, 
our results can be replicated with our public information datasets or, alternatively, the fuzzy model can 
be easily applied to investigate innovation risk at different laboratories with alternative datasets. 
1.1. Alternative R&D strategies 
Large, R&D-intensive pharmaceutical companies are in the business of permanent innovation. Ideally, 
they should have a stable pipeline of new drugs over time that receives sufficient approvals, year after 
year, from agencies such as the Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA), in order to create value for as many stakeholders as possible. If large pharma labs find 
a way to enhance strategic decisions when configuring the global portfolio of clinical trials, this  is going 
to be good news not only for patients and shareholders but also for regulators and other parties interested 
in a better functioning of the drug discovery process and eventually for the whole healthcare sector. To 
this end, adequate financing of the drug discovery process through internal R&D expenditure and 
financial transactions is fundamental. Thus, it is of utmost importance to balance strategic issues and 
financial considerations when designing the composition of a R&D portfolio (Carlsson et al., 2007; Lo 
Nigro et al., 2016; Guo et al., 2018).  
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Exploring a sample of 37 pharmaceutical laboratories, Gascón et al. (2017) find that most of the large 
companies in this industry are either fully efficient or close to the efficient frontier. Having said that, 
there is room to push the frontier forward by taking better-informed strategic decisions about how to 
configure the portfolio of clinical trials. Assessing correctly the innovation risk level of alternative 
clinical trial strategic decisions is very relevant to the decision making process. 
At this point, it should be highlighted that there are several alternative paths for achieving valuable and 
sustainable innovation. Some innovators at the frontier have a preference for creating knowledge inside 
the organization while others to look outside in order to push innovation (Lowman et al., 2012; Macher 
and Boerner 2012; Schuhmacher et al., 2013; Honig and Hirsch, 2016; Schuhmacher et al., 2016; 
Trusheim et al., 2016; Gascón et al., 2017). Whatever organizational alternatives are selected, there will 
be innovation risks that need to be quantified and managed. 
Different strategic choices and attitudes toward risk, interplaying with those of competitors of different 
sizes and R&D characteristics, will yield different outcomes. In this paper, we are mostly concerned 
with the strategic choices made by large pharmaceutical firms aimed at managing innovation risk in 
uncertain environments. In such a context, fuzzy methodologies can make a difference. Interestingly, 
fuzzy applications have been previously proposed for supporting decision-making processes when 
managers are faced with complex, uncertain, and risky environments, and the dataset is relatively small 
but with a high number of attributes; see e.g. Li et al. (2011) and Guo et al. (2018). In our case of large 
pharmaceutical laboratories, there are also many attributes; however, the dataset is extremely large and 
we need to integrate these large and diverse data sources. In this sense, a team of experts have played a 
crucial role in the development of the FIS. Finally, we highlight that all the datasets that we employ in 
this work are publicly available. 
1.2. Modelling innovation risk 
Several aspects make it difficult to evaluate, in a simple manner, the innovation risk inherent in a given 
pharmaceutical firm. In this paper, we develop a fuzzy evaluation model for assessing the global 
innovation risk associated with  the portfolio of clinical trials at pharmaceutical companies that is built 
on four factors that our experts consider crucial to an adequate assessment of innovation risk : (1) R&D 
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expenditure (R&D); (2) Number of announced Financial Transactions (NFTs); (3) Probabilities of 
success related to authorized New Chemical Entities (NCEs x Prob); and (4) Probabilities of success of 
yet-to-be-approved drugs, approximated through Clinical Trials (CTs x Prob). All the sources of data 
that we used for the construction of inputs are described in Table A.1 (Appendix A).  
Under these circumstances, three FIS are designed to integrate all these information sources with the 
aim of supporting decision-making processes at large pharmaceutical firms. Fuzzy inference systems 
adequately emulate human reasoning in decision-making processes based on rules from ill-defined or 
vague data (Lin, 2010) —as has already been proved in many other ambits (Puente et al., 2002; Gascón 
et al., 2007; García et al., 2013). This approach is therefore perfectly applicable for managing the 
pipeline of innovative drugs in large pharmaceutical laboratories.  
We consider the four factors and we make use of the expert knowledge embedded into the risk 
assessment model through the knowledge base defined for the FIS —expressed by a set of If-Then 
rules—, we are able to quantify the innovation risk associated with a large pharmaceutical laboratory 
from two perspectives: those of the Chief Financial Officer (CFO) and the Chief Innovation Officer 
(CIO). In addition, and in order to avoid potential biases in the definition of the evaluation system 
structure, we suggest a new method based on 2-tuples. This is aimed at achieving an agreement between 
experts on the definition of the partitions of their variables and their rule bases. 
All in all, the proposed methodology allows us to manage the high uncertainty inherent in the definition 
of the knowledge bases needed to develop the evaluation model and facilitates understanding of the 
evaluation process, constructing a conceptual framework similar to what an expert in the pharmaceutical 
laboratory sector would have in mind. 
1.3. Paper structure 
The rest of the paper is structured as follows. In Section 2, the variables used in the evaluation model 
are described, as are the sources from which these variables come. In Section 3, the methodology 
proposed for the design of the model is described. This methodology will permit the evaluation of the 
innovation risk of large pharmaceutical laboratories. Section 4 describes how the methodology is applied 
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to the particular cases of 31 large pharmaceutical firms. In this section, we also discuss the results 
obtained. Lastly, in Section 5, we present our conclusions and reflect on some avenues for future work.  
2. Data sources, variables and risk evaluation model 
To capture the innovation risk of companies in the pharmaceutical industry, we have accounted for the 
present challenges of drug discovery. Advances in science and technology allow pharmaceutical 
laboratories to use more varied ways of organizing their acquisition of knowledge in order to foster 
innovation. The strategic choices taken by laboratories that condition innovation risk are numerous and 
inter-related. Therefore, we need to choose the most relevant variables to obtain a decision-making 
model that helps them determine the desired level of innovation risk. We have embedded this compound 
of knowledge into the FIS with the aid of a team of experts. First, an expert in the biochemical 
characteristics of authorized new chemical entities and clinical trials. Second, an expert in the 
pharmaceutical sector, whose laboratory is not part of our sample. Third, a group of experts in the 
economic and financial variables of value creation at pharmaceutical laboratories.  
Each of the four inputs (factors) of our fuzzy innovation risk model, i.e., (1) R&D; (2) NFTs; (3) NCEs 
x Prob; and (4) CTs x Prob, has its own data requirements. We describe in detail, in Appendix A, the 
different datasets used in setting up the model. We also explain our choice based on our experts 
knowledge as well as on previous research articles and literature reviews. Some of these variables have 
previously been employed in Gascón et al. (2017); in particular, those variables related with the first 
FIS of the model. Others are specific to the risk evaluation model that we develop in this paper; those 
related to the second FIS of the model. Our final sample comprises 31 large pharmaceutical firms. In 
Table A.1 (Appendix A), we have summarized all the problems encountered while merging different 
sources of data, as well as the solution given to these problems, in order to construct the four inputs of 
the fuzzy model.  
2.1. Input variable 1 – R&D: Pharmaceutical laboratory internal R&D capability 
Pharmaceutical laboratories are technology-based organizations that may improve their innovation 
performance by means of: (1) prior experience in a particular therapeutic area (or disease) that we will 
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classify according to ATC codes; and (2) diverse overall experience (ATC code diversity). Laboratories 
with more diverse experience have access to a greater range of knowledge (which can be transferred to 
a new therapeutic area) than organizations with a more homogenous knowledge base. The greater their 
R&D capabilities, the more their successful and unsuccessful prior experiences in a particular 
therapeutic area and the more diverse their overall experience in different therapeutic areas (Granstrand, 
1998; Breschi et al. 2003; Almeida and Phene, 2004; Suzuki and Kodama, 2004; Macher and Boerner, 
2006; Macher and Boerner, 2012; Boh et al., 2014; Garzon-Vico et al., 2016). 
Size per se is not a guarantee of lower innovation risk, and large organizations may be less innovative 
than smaller ones. However, competition will eliminate inefficient organizations, both large and small, 
from the market. Even among large pharmaceutical laboratories, some are larger than others. Larger 
laboratories are able to diversify more and invest in promising drugs in more varied therapeutic areas or 
diseases. Thus, we expect large efficient pharmaceutical laboratories to organize their R&D activities in 
an efficient manner as in Gascón et al. (2017). Large laboratories with a greater internal R&D capability 
have the potential to organize their R&D resources in more varied ways and to draw from experience. 
Ceteris paribus, we expect laboratories with a greater internal R&D capability to control better and 
reduce relative innovation risk. 
2.2. Input variable 2 – Number of Financial Transactions (NFTs): External R&D 
Competitive financial markets allocate funds to the organizations with the greatest potential for 
implementing new processes and technologies. Thus, laboratories that are active in financial transactions 
and understand which R&D investments are fundamental key will be more successful in bringing 
innovative drugs to the market with lower innovation risk. The way innovation is financed shapes the 
type of R&D that is undertaken (Haleblian and Finkelstein, 1999; Macher and Boerner, 2012; Bena and 
Li, 2014; Kerr and Nanda, 2015; Nanda and Rhodes-Kropf, 2017).  
Thus, laboratories can manage the R&D resources needed to simultaneously promote innovation in the 
portfolio of new drugs in two alternative ways. New promising drugs may be developed based on a 
combination of internal R&D effort and/or financial transactions (external R&D effort). See Figure 1 in 
Gascón et al. (2017). Our first input (pharmaceutical laboratory internal R&D capability) measures the 
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internal potential of laboratories to be innovative over time and manage their innovation risk while, our 
second input, announced NFTs, measures the ability to rearrange the portfolio of new drugs by 
externally acquiring (and/or selling) new knowledge while keeping greater control of the innovation 
process than in cooperation arrangements. Thus, financial transactions by pharmaceutical laboratories 
in order to acquire or sell certain drugs (or laboratory R&D divisions) are an alternative way of managing 
the portfolio of promising drugs at different stages of the pipeline. They are also a way of acquiring 
R&D strength or of discarding an R&D line that is no longer strategic and/or efficient See Table A.1 
(Appendix A) for detailed information about factors in our model. 
2.3. Input variable 3 – Probabilities of success associated with authorized New Chemical Entities 
Firms with greater levels of experience in a given therapeutic area (disease or condition area) tend to 
obtain greater innovation performance than those with little experience (Macher and Boerner, 2012; 
Garzon-Vico et al., 2016). Thus, two laboratories with similar internal R&D capabilities and similar 
NFTs may have different success rates in terms of previously approved new drugs and different pipeline 
risk. Also, different laboratories will tend to make different strategic choices. These laboratories may 
choose different strategic approaches. We try to capture these strategic arrangements by taking into 
account previous successes. In our paper, the success of a laboratory is measured in terms of the number 
and type of authorized NCEs (new drugs in each ATC code per lab) previously approved by EMA or 
FDA, and we consider this input as a proxy for lower future innovation risk. More successful approvals 
imply that the laboratory had the required knowhow and knowledge to successfully bring a new drug to 
the market, which reduces innovation risk and/or accelerates drug development approval. After 
identifying NCE approvals by EMA and/or FDA in our sample of pharmaceutical laboratories, and with 
the aid of our experts, we link drug success information with estimates of average probability of success 
from phase I to approvals in different ATC codes (classification of therapeutic areas). See Tables A.2 
and A.3 (Appendix A) for the probabilities of success from phase I to approval for different ATC codes. 
2.4. Input variable 4 – Probabilities of success of Clinical Trials in phases I to IV 
As indicated by Khanna et al. (2015) and Garzon-Vico et al. (2016), when successful drug approvals are 
considered without taking failures into account, a core part of learning and the innovation risk picture is 
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missed. In order to account for the probability of failures and the portfolio of promising drugs in different 
pipeline phases, with the aid of experts, we combine information from CTs and conditions (disease areas 
linked to ATC codes) with information regarding the probability of success from a given phase to 
approval of each CT. See Table A.4 (Appendix A) for the association of Clinicaltrials.gov conditions 
(disease areas) with ATC Codes. 
Our fourth input are Clinical Trials (CTs) from our sample of pharmaceutical laboratories in phases I to 
IV during the period 2008 to 2013. CTs provide information of various kinds. In our case, we aim to 
approximate the innovation risk associated with the strategic choices made by pharmaceutical 
laboratories when deciding in which therapeutic areas or diseases they would like to be R&D efficient 
and competitive. By combining these two sources of information, we obtain a picture of the willingness 
of the laboratory to assume innovation risk in diseases with higher (or lower) probability of success. See 
Table A.5 (Appendix A) for an association of Clinicaltrials.gov conditions (disease areas) and 
probabilities of success from the corresponding pipeline phase to approval for each ATC Code. 
We try to capture coordination in clinical trials (CTs) by considering two alternative ways of analyzing 
CTs: (1) focusing only on the main indication (disease or condition) that is being targeted by a given 
CT; and (2) focusing on a maximum of six main indications (diseases) that are being targeted by a given 
clinical trial. This second approach captures R&D coordination efforts. Thus, we consider CTs with and 
without duplications in the targeted diseases. We adjust for CTs which target more than one indication 
(disease), up to a maximum of six indications (diseases). See Table A.6 (Appendix A).  
2.5. Output variable 
Drug R&D performance and the variables used to explain this performance vary depending on the 
approach chosen by those who study the innovation field. Drug performance has been measured in the 
past as drug approvals, drug R&D submission time or a combination of approvals and failures (Cockburn 
and Henderson, 2001; Danzon et al., 2005; Macher and Boerner, 2012; Khanna et al. 2015; Garzón-
Vico et al., 2016). In our paper, the output variable proposed is the global innovation risk level associated 
with a given large laboratory based on the assessment assigned to the four above-mentioned input 
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variables. We have calibrated the fuzzy model and embedded knowledge with the aid of experts in 
portfolio risk management and in pipeline management.  
 
2.6. Risk evaluation model 
With the aim of evaluating global innovation risk, three sequenced evaluation subsystems were 
generated according to the model structure shown in Figure 1. 
 
Figure 1. Overview of the proposed risk assessment model. 
Note. Considering the financial side of innovation risk, input 1 is R&D expenditure in a pharmaceutical laboratory and input 2 
counts the number of announced financial transactions by each pharmaceutical laboratory. See Gascón et al (2017) for more 
information on how inputs 1 and 2 are calculated. Considering the pipeline side of innovation risk, Input 3 computes, at the 
laboratory level, the aggregate probability of success of authorized new chemical entities by EMA and FDA adjusting for the 
disease area of each drug in a given laboratory, and input 4 considers the probabilities of success of clinical trials in a given lab 
adjusting for the phase and the disease area of each clinical trial. Clinical trials come from the Clinicaltrials.gov website  and 
probabilities come from Thomas et al. (2016). 
The first subsystem captures the financial and funding side of innovation risk while the second 
approximates the pipeline side. The first subsystem determines the financial side of innovation risk of a 
laboratory (R1) according to the size of its R&D expenditure and the number of financial transactions, 
NFTs. The second subsystem determines the pipeline side of innovation risk of a laboratory (R2) 
according to the value of its factors: probability of success of approved NCEs and probability of success 
of CTs.  
We link information on NCEs and CTs with information on the probability of success of drugs in 
different phases (phase I to approval in the case of authorized NCEs, and phase I to IV to approval in 
the case of CTs) to approximate pipeline risk. Based on the risk values obtained in these two subsystems, 
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use of the third subsystem makes it possible to obtain the overall innovation risk associated with each 
laboratory (R3). In this third subsystem, we allow for two different perspectives, the CFO perspective 
and the CIO perspective. Figure 1 shows the risk assessment model proposed for a large pharmaceutical 
laboratory.  
Pharmaceutical firms with greater internal and external R&D resources are able to choose between high 
innovation risk (growth objective) and low innovation risk (stability objective). Also, larger firms may 
be sellers or buyers when involved in financial transactions. Smaller firms may have a higher innovation 
risk or a high probability of being involved in financial transactions as sellers. We try to capture the 
impact of different strategies on innovation risk. 
3. Methodology 
One of the main contributions of this paper is of a methodological nature. The methodology aims to 
evaluate innovation risk in large pharmaceutical laboratories given their strategic choices in four 
different dimensions (inputs), according to the proposed evaluation model described above. 
In order to develop evaluation models such as the one proposed, classical crisp methodologies can be 
used (e.g. aggregation operators, factor weighting, and regression techniques, among others). However, 
problems may arise when implementing them because it is difficult to process the intrinsic uncertainty 
of an evaluation mechanism that is defined by a knowledge base that is consensual and appropriate for 
the problem being studied (Castro-Lopez et al., 2017). Moreover, various artificial intelligence 
techniques have proven their suitability in production, service and management areas, helping make 
decisions and supporting the efficient design of processes and practical applications. Some of these 
methods may be difficult to apply in the context of this study. For example, the Fuzzy AHP method 
(Chatterjee et al., 2018) requires finding experts that are able to establish pairwise comparisons of the 
attributes involved in the model; while the Interval Type-2 Fuzzy Method (Sari et al., 2015) may be 
difficult to apply by experts from pharmaceutical sector unfamiliar with computer science techniques. 
Nonetheless, other artificial intelligence techniques, such as the FIS –methodology used in this study to 
assess the innovation risk of pharmaceutical laboratories – have been successfully applied in multiple 
fields (medicine, environment, logistics, aeronautics, marketing, banking, among others), which 
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demonstrates its suitability to manage uncertainty through the appropriate use of natural language and 
to replicate the reasoning of human beings in the decision-making processes that handle vague and 
imprecise data (Lin, 2010; Skorupski, 2015; Vadiati et al., 2016; Sardesai et al., 2016).  
The use of FIS to assess the innovation risk of pharmaceutical laboratories has various advantages. It 
facilitates the consensual definition of the input variable ranges of the model and their underlying rating 
labels. It allows to verify the consistency of the knowledge included in the rule bases agreed by the 
experts to define the risk assessment procedure. In addition, the use of FIS does not necessarily require 
a prior normalization of the variables in the model and allows the knowledge necessary to value them 
to be added in a guided and intuitive manner based on the above mentioned rule bases. 
Regarding previous research on innovation in large pharmaceutical firms, the analysis by Garzón-Vico 
et al. (2016) is close to this study in terms of the sample of pharmaceutical laboratories. However, their 
methodology (competing risk analysis) and their objective (conditions under which firms’ R&D 
experiences might have stronger or weaker effects on innovation capabilities) are quite different to ours. 
Tavana et al. (2015) employ an approach built on multi-step, hybrid, fuzzy, multi-criteria decision 
making (MCDM). They use two fuzzy Data Envelopment Analysis (DEA) models to measure the 
relative efficiency of large pharmaceutical companies and establish a ranking. We, however, focus on 
developing an evaluation model that allows us to measure innovation risk. 
To the best of our knowledge, there is no other FIS research aiming specifically to assess the innovation 
risk of pharmaceutical laboratories in a consensual way. However, FIS has been used in similar settings, 
e.g. to analyze the characteristics of the market for generic pharmaceutical drugs (Gascón et al., 2007; 
Puente et al., 2011). 
3.1. FIS for the evaluation of the proposed model  
The definition of a FIS is based on the theory of Fuzzy Sets (Zadeh, 1965). A FIS facilitates management 
of the uncertainty inherent in the definition of the knowledge needed to evaluate a model, making it 
possible to represent its functioning in a way that is both realistic and close to human reasoning 
(Lootsma, 2013). In these systems, the model variables are defined linguistically, and their values are 
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associated with ordered concepts (e.g. "low", "medium" and "high"); this differs substantially from 
classical variables whose values are exclusively numerical (Driankov et al., 1996). In the proposed 
model, the way a level of innovation risk is determined (depending on different levels of its independent 
variables) may be subject to a high degree of uncertainty. Treating the variables in a linguistic way 
simplifies the definition of the evaluation criteria given by the experts. In addition, as will be shown 
below, the interpretation of knowledge for risk assessment that is embedded in the FIS is very intuitive. 
The FIS knowledge bases have been defined according to the expert knowledge that we gained on 
innovation risk assessment. To this end, we have worked closely with three experts/groups of experts, 
who played different roles in shaping and validating our fuzzy evaluation model, given their diverse 
backgrounds. In more detail, these are: (i) a PhD in Biochemistry; (ii) a manager with large experience 
in the pharmaceutical industry; and (iii) a group of academics specialised in financial management and 
value creation. In the development of our work, we have had periodic meetings with the team of experts. 
Their individual roles are discussed below. We do not reveal their names for confidentiality reasons.  
First, the PhD in Biochemistry expert helped us combine knowledge on authorised new chemical entities 
(NCEs) and Clinical Trials (CTs) with information on success probabilities for different diseases 
(conditions) and ATC codes. In this sense, his/her knowledge of the disciplines of biochemistry and 
pharmacology has been very useful when constructing the knowledge base and when linking coherently 
the different datasets. Second, the expert in the pharmaceutical sector works currently as a manager in 
sales and market access in a company operating in the pharmaceutical sector in the North of Spain. 
His/her current tasks include the promotion of new projects within the company (intra-entrepreneurial 
activities) that create value for doctors and hospitals. In this sense, his/her knowledge about competition 
among pharmaceutical laboratories and about publicly available information regarding the marketing of 
existing and potential new drugs launched by competitors has been extremely useful when embedding 
the knowledge regarding the pipeline side of innovation risk as well as when seeking the validation of 
the model. Third, our group of experts in financial management and value creation are colleagues that 
work at the University of Oviedo, Autonomous University of Madrid, and University of Valladolid. Our 
colleagues helped us embedding the knowledge related to portfolio risk management and the financial 
part of innovation risk. 
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The FIS knowledge base is defined based on the expert knowledge gained on innovation risk assessment. 
We therefore decided to define three FIS sequenced according to the proposed model. Each subsystem 
assigns a level of innovation risk based on the levels of two input variables. To design the structure of 
the inference systems, we adopt the following premises:  
(1) To homogenize the problem, the experts first agreed to establish the same number of labels for all 
the input and output variables of the different subsystems. After considering three options (three, five 
and seven levels), through the mode of expert evaluations, it was decided to use three levels for the input 
variables (Low, Medium, High) and five levels for the output variables (Very Low, Low, Medium, High, 
Very High). Interestingly, this structure makes the rule bases not too wide (9 rules) and provides 
sufficient discrimination in the assignment of output labels to the said rules. As we will discuss latter, 
this fact causes certain model variables (in particular, R1 and R2) to have different partitions depending 
on whether they are treated as inputs or outputs in the relevant subsystems. 
(2) For the purpose of semantic representation, we use triangular or trapezoidal labels, which many 
authors consider sufficiently robust to represent the vagueness of the linguistic evaluations of the 
considered sources of information (Delgado et al., 1992). Additionally, we use strong fuzzy partitions 
(Casillas et al., 2003) because they have good properties for comprehensibility and meet important 
semantic constraints like distinguishability, normalization, coverage or overlapping (Mencar and 
Fanelli, 2008). 
Adopting these premises facilitates the consensual definition of both, the variable partitions and the rule 
bases of the proposed FIS. Thus, we have adopted a symbolic translation method based on 2-tuples to 
partition the variables, inspired by the work of Herrera and Martinez (2000). This methodological 
approach allows us to reach an agreement on the basis of the judgement of several experts regarding 
different structural alternatives of the label cores assigned to each variable. Each 2-tuple (si, i) 
represents linguistic information of the degree of agreement of an expert with different alternatives of 
cores, with si being a fuzzy term of linguistic preference from an original set of fuzzy terms S, and I, a 
value within the interval [-0.5 , 0.5), representing the symbolic translation. The considered original set 
of fuzzy terms, S, is displayed in Table 1. 
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Table 1. Original set of fuzzy terms of linguistic preference assignable to each core structure. 
 Label  Trapezes 
S0 D (Disagreement) 0 0 0.3 0.4 
S1 P (Parcial Agreement) 0.3 0.4 0.4 0.7 
S2 T (Total Agreement) 0.4 0.7 1 1 
 
By way of illustration, Figure 2 includes four alternative core structures that were proposed for the input 
variables R&D and NFT, in the first subsystem —it would also be possible to propose alternative cores 
for each label of the partition individually-.  
 
Figure 2. Alternative core structures for the variables R&D and NFT. 
The assessments made by our team of experts for these four structures are represented in Table 2. 
Table 2. Expert fuzzy evaluations for different core structures.  
 
Note. We use empty space for the evaluations related to the label ‘D-disagreement’. 
 
To reach an agreement on the evaluation of the different experts with respect to each structure, we 
averaged the orders of their assigned fuzzy terms (Extended average). For example, EA (Struc_1) = (0 
* 1 + 1 * 2 + 2 * 2) /5 = 1.2. Next, these values were transferred, through a symbolic translation, to their 
related 2-tuples in the interval [-0.5, 0.5). These 2-tuples measure the consensual preference label and 
its displacement with respect to the original set of preferences (either to the left or to the right). Figure 
Struc_1
Struc_2
Struc_3
Struc_4
0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
LOW MED HIGH
Struc_1 Struc_2 Struc_3 Struc_4
Exp1 T P
Exp2 P T
Exp3 T P P
Exp4 P T
Exp5 P T
Extended
Average 1,2 1 0,2 0,8
2-tuples: (P, 0.2) (P, 0) (D, 0.2) (P, -0.2)
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3 illustrates this process for the previous value of Struct_1. Subsequently, the core-structure with the 
highest aggregate preference according to its lexicographical disposition (in this case, "Struc_1") is 
selected. Finally, taking into account this selected core structure, and considering that the partition needs 
to be strong, the final semantic of each partition is obtained by central symmetry between every two 
consecutive labels.  
 
Figure 3. Symbolic correspondence of EA=1.2 with 2-tuple=(P, 0.2). 
Figure 4 illustrates the partition obtained for the input variables of the first subsystem.  
 
Figure 4. Consensual partition for the variables R&D and NFT. 
Figure 5 shows the agreed partitions for the input and output variables for all the FIS subsystems of the 
proposed model employing this procedure. 
0 1 2 3
s0 s1 s2
D P T
1.2
(S1 ,  0.2)
( P ,  0.2)
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Figure 5. Defined partitions for all the input and output variables in the risk evaluation model. 
To define the rule bases, we used the same 2-tuple methodology. Therefore, the experts assess their 
degree of agreement with respect to the assignment of each possible output label in all the rules. Then, 
by means of the translation to 2-tuples of the averaged valuation for each potential output label, it is 
selected in each rule the one that provides the highest degree of acceptance. Figure 6 shows the rule 
bases obtained using this method for the three subsystems (the third subsystem shows two different rule 
bases, the first from the point of view of the CFO and the second from the point of view of the CIO). 
As an example, the third rule for the determination of financial risk (R1) would be understood as [If 
R&D is Low and NFT is High, then R1 is High]. 
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Figure 6. Rule bases for the three defined fuzzy subsystems. 
 
3.2. Mamdani Inference: Study of inference surfaces for the subsystems of the model 
Relying on everything defined above, Mamdani-type FIS trigger the inference process given the crisp 
values of the four input variables of the proposed model. These FIS seek to infer a crisp numerical value 
for each output variable as a function of the crisp values given to their corresponding input variables. 
This process consists of five main stages (Mamdani and Gaines, 1981): (1) fuzzification; (2) application 
of logical operators in every rule’s antecedent; (3) implication in every rule’s consequent; (4) 
aggregation of all rules’ consequents; and (5) defuzzification of the final aggregate.  
First, these crisp input values are fuzzified, which refers to their conversion from real to truth values, 
between 0 and 1, according to the labels intercepted in the corresponding partitions in all the rules. 
Second, by applying appropriate operators to these intercepted values in the antecedent of each rule —
following the logical connectives that link its variables—, a global truth value for each rule is calculated. 
We note that the "min" operator is commonly considered for the “and” connector. Third, the global truth 
value of a rule (activation level) is transmitted to its consequent in the implication stage. It is generally 
generated by truncating the label of its output variable to that activation level. Next, the truncated output 
labels of all active rules are grouped in the aggregation stage (commonly overlapping them and choosing 
the path of maximum truth values). Finally, the aggregated fuzzy set must be defuzzified to obtain the 
final crisp value of the output variable, usually by calculating the abscissa of its centre of gravity.  
L M H L M H
L VH VH H L VH VH H
M H M M M H M L
H M L VL H L L VL
L M H L M H
L VL L L L VL M H
M M H H M L H VH
H H VH VH H L H VH
*CFO perspective **CIO perspective 
R2
R1
R&D CT
Global Innovation 
Risk (R3*)
R2
R1
Global Innovation 
Risk (R3**)
Financial side of 
Innovation Risk (R1)
NFT Pipeline side of 
Innovation Risk (R2)
NCE
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By way of example, Figure 7 illustrates the inference process of the initial subsystem, labelled 
as RiskPham1, for the laboratory “Bayer” (whose normalized input crisp values are R&D=0.51 
and NFT=0.43). In this figure, each row represents a rule in the said subsystem, while the final 
block of the last column represents the final aggregate whose center of gravity (abscissa) will 
be the risk R1 that we obtained for the laboratory. First, we fuzzify the aforementioned crisp 
values in the input variables of all the rules, obtaining the truth values shaded in the first two 
columns (i.e., partial activation levels). Second, and given that “AND” is the logical connector 
in the antecedent of the rules, the global activation level of each rule is obtained as the minimum 
of the partial activation degrees of its input variables —consequently, in this examples, only 
rules 5, 6, 8, and 9 are activated. Third, the implication to the consequents of the activated rules 
occurs, truncating their output labels to the global activation levels of the previous step (that is, 
the shaded areas of the last column). Fourth, the aggregation of the truncated labels of all rules 
takes place by means of the MAX method, which involves the superposition of the truncated 
labels of all rules and the selection of the path of maxima in the domain of the output variable 
(shaded area in the last block of the third column). Fifth and finally, the final aggregate of the 
previous step is defuzzified through the gravity-center method, which leads to obtaining the 
risk R1 for each laboratory (in this case, 0.38). 
 
Figure 7. Fuzzy inference process of the initial subsystem, RiskPharm1, for the laboratory “Bayer”. 
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Similarly, the second inference subsystem, named RiskPharm2, operates by considering the crisp values 
of its input variables, CT and NCE, according to the partitions and rules agreed upon for it. This allows 
to estimate the risk R2 for each pharmaceutical laboratory. Finally, to determine the Global Innovation 
Risks (R3 * and R3 **) of the different laboratories, the inference subsystems RiskPharm31 (CFO 
perspective) and RiskPharm32 (CIO perspective) act on the previously obtained values of risks R1 and 
R2 —which are interpreted in this case as inputs—, according to the different knowledge bases defined 
for them. 
Although the methodology may appear to be operationally complex, there are multiple software 
programs that enable researchers to carry out this evaluation process by simply defining the labels 
associated with the system variables and the rule base that incorporates the decision knowledge. We use 
the software Matlab fuzzy logic toolbox ® v. 2.0 (Chen and Klein, 1997) to develop our FIS. A detailed 
explanation of the operation of this software can be accessed from Mathworks Web 
(http://www.mathworks.com/products/fuzzy-logic/).  
In addition, MATLAB allows one to easily concatenate a set of FISs. In this sense, we can evaluate at 
the same time a wide sample of laboratories. The following code lines illustrates how we have 
concatenated the three subsystems.  
R&D  %Stores the crisp values of the R&D variable for the sample of 
laboratories% 
NFT  %Idem for NFT% 
CT  %Idem for CT% 
NCE  %Idem for NCE% 
Sys1=Readfis(‘ RiskPharm1.fis’);  %Reads the FIS structure that allows us to evaluate R1% 
Sys2=Readfis(‘ RiskPharm2.fis’); %Idem for R2% 
Sys31=Readfis(‘ RiskPharm31.fis’); %Idem for R31 (CFO perspective)% 
Sys32=Readfis(‘ RiskPharm32.fis’); %Idem for R32 (CIO perspective)% 
R1=Evalfis([R&D NFT], Sys1); %Estimates the R1 values for the sample of laboratories% 
R2=Evalfis([CT NCE], Sys2); %Idem for R2% 
R31=Evalfis([R1 R2], Sys31); %Idem for R31 (CFO perspective)% 
R32=Evalfis([R1 R2], Sys32); %Idem for R32 (CIO perspective)% 
Note. The .fis files, generated with MATLAB, can be accessed in the online dataset repository.   
The congruence of the evaluations obtained through the designed FIS can be easily and intuitively 
investigated through the inference surfaces supplied by each model’s subsystem. These maps represent 
the scores of the output variables by the height of the surface at each point. By way of example, Figure 
8a shows the evolution of the financial risk “R1” evaluation as a function of the “R&D” and “NFT” 
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values. The risk R1 of each laboratory should lie on the surface we show (by way of illustration, we 
show the position of the risk R1 for the laboratory ‘Bayer’ according to the data employed in the 
inference process previously discussed). The obtained surface proves that the larger the values of R&D 
and NFT variables, the higher the financial risk “R1”, being the gradient more pronounced for the R&D 
variable. Figure 8b shows the evolution of the innovation risk “R2” evaluation as a function of the “CT” 
and “NCE” values. Unlike the previous case, we observe how we obtain increasing values of innovation 
risk for decreasing values of the input variables –as it can be seen in the horizontal axis of the map, 
corresponding to the variation of the values of these variables CT and NCE-. It is also observed how, 
according to the knowledge inserted in this system, the variable that causes higher gradients in the level 
of innovation risk is "TC" —that is, a relatively small decrease in this variable causes significant 
increases in innovation risk. 
Finally, Figures 8c and 8d show the evolution of global risk "R3" as a function of the "R1" and "R2" 
values, from the point of view of the CFO or the CIO, respectively. Based on the knowledge inserted 
for determining the global risk, an inverse behaviour is observed between both surfaces, showing the 
need to achieve a trade-off between the interests of the Financial Management and the Innovation 
Department. 
In general terms, fuzzy inference models can be constructed with pre-existing knowledge of the 
behaviour of the system to be modelled and / or with the knowledge provided by a panel of experts on 
such behaviour. In the first case, the validation of the rules extracted from pre-existing knowledge is 
usually carried out by quantifying an error measure —such as the root mean square error (RMSE)— of 
the outputs given by the model and those provided by the real system. In the second case, generally it is 
not possible to establish a validation procedure for the rules generated given that the outputs of the real 
system cannot be known; see e.g. Rigatos and Zhang (2009). In our model, we use "Mamdani" inference 
rules, which are agreed by experts through an innovative 2-tuple method, that cannot be validated against 
the innovative risk values of real-world pharmaceutical laboratories due to the lack of published official 
data. Having clarified this important point, our model has been constructed in a rigorous and consensual 
manner (with the important contribution of the expert team). Moreover, in all cases, these surface maps 
were shown to the experts who allowed us to reach an agreement on the knowledge base. They showed 
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a high degree of acceptance with respect to the global behaviour defined by the maps and suggested to 
evaluate and discuss the results of the model according to the data of 31 large pharmaceutical 
laboratories. 
 
a) Risk R1 from R&D and NFT 
Note. Risk R1 captures the evolution of the financial dimension of innovation risk according to the intensity of internal R&D 
expenditure and according to the number of financial transactions announced by a pharma lab in order to buy and sell other 
pharmaceutical laboratories. 
 
 
b) Risk R2 from NCEs and CTs 
Note. Risk R2 captures the evolution of the pipeline (strategic) dimension of innovation risk according to the number of new 
chemical entities (NCE) authorized by EMA and FDA and according to an aggregate figure of the number of clinical trials 
(CT) in the different disease groups and different phases I to IV of clinical trials. 
 
Bayer (R1=0.38) 
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c) Global innovation Risk R3 from R1 & R2 (CFO Perspective) 
Note. Innovation risk R3 from a CFO perspective captures the global innovation risk from a Chief Financial Officer 
perspective where the financial side of innovation risk, R1, is more relevant to the analysis than the pipeline side of 
innovation Risk, R2. 
 
d) Global innovation Risk R3 from R1 & R2 (CIO Perspective) 
Note. Innovation risk R3 from a CIO perspective captures the global innovation risk from a Chief Innovation Officer 
perspective where the pipeline (strategic) side of innovation risk, R2, is more relevant to the analysis than the financial side 
of innovation Risk, R1. 
Figure 8. Inference Maps for all the fuzzy subsystems of the risk evaluation model. 
4. Application of the decision-making system to 31 large pharmaceutical laboratories: Results, 
evaluation of the model and discussion 
Although we obtained intermediate results in the first two subsystems (see Appendix B), we will focus 
mainly on the results obtained in the third subsystem. The third FIS is a weighted combination of the 
previous two subsystems, as demonstrated by the very definition of their respective rule base. Depending 
on the type of user of the fuzzy subsystems, more weight will be allocated to the first subsystem 
(financial side of innovation risk) or, alternatively, to the second subsystem (pipeline side of innovation 
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risk). If we are analyzing strategic issues and decision making from the point of view of the CFO, then 
the first fuzzy subsystem should be assigned a greater weight given that it is the most relevant subsystem 
for obtaining a global vision of the internal and external R&D budget. Alternatively, if we are analyzing 
pipeline strategic issues from the point of view of the CIO, then the second fuzzy subsystem should be 
allocated a greater weight given that it is the most relevant subsystem for deciding in which therapeutic 
areas (or diseases) and phases I to IV the pharmaceutical laboratory is going to be more active, given 
previous successful approvals and given the probabilities of success of different drugs depending on the 
class of disease(s). 
Table 3 contains the correlation matrix of the four innovation risk measures (CFO perspective with CT 
duplications, CIO perspective with CT duplications, CFO perspective without CT duplications and CIO 
without CT duplications). As expected, there is a very high correlation (almost 100% in one case and 
97% in the other) between both CFO perspectives (with and without CT duplications) and between both 
CIO perspectives (with and without CT duplications). This implies that there are no major differences 
between the estimation innovation risk using CTs with duplications or CTs without duplications.  
Table 3. Correlation matrix of the four innovation risk measures 
 CFO CT dup CIO CT dup CFO CT nodup CIO CT nodup 
CFO CT dup 1.0000 - - - 
CIO CT dup 0.6137 1.0000 - - 
CFO CT nodup 0.9962 0.6111 1.0000 - 
CIO CT nodup 0.6141 0.9745 0.6296 1.0000 
Note. CFO stands for Chief Financial Officer and CIO stands for Chief Innovation Officer. CT no dup is our acronym for the 
main indication (targeted disease) of each clinical trial while CT dup is our acronym when we consider a maximum of six main 
indications (targeted diseases) that are being targeted simultaneously by a given clinical trial. CFO CT dup and CIO CT dup 
are the CFO and CIO perspectives with CT duplications.  CFO CT nodup and CIO CT nodup are the CFO and CIO perspectives 
without CT duplications. 
We try to capture this coordination by considering two alternative ways of analyzing CTs: (1) focusing 
only on the main indication (disease) that is being targeted by a given CT; and (2) focusing on a 
maximum of six main indications (diseases) that are being targeted by a given clinical trial. This second 
approach captures research coordination efforts. Thus, we consider CTs with and without duplications 
in the targeted diseases. We adjust for CTs which target more than one indication (disease), up to a 
maximum of six indications (diseases). However, the correlation between the CFO perspective with CT 
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duplications and the CIO perspective with CT duplications is 61% while the correlation between the 
CFO perspective without CT duplications and the CIO perspective without duplications is also 61%. 
Given these results, we suggest that the CFO perspective and the CIO perspective capture different 
aspects of innovation risk. 
In order to interpret our results, it is important to note that high (low) innovation risk is not bad per se. 
There may be low-innovation-risk laboratories that create (destroy) value, or high-innovation-risk 
laboratories that also create (destroy) value. With the aim of better understanding these results, Figure 
9 illustrates the global innovation risk associated with the 31 firms that we considered for CTs with and 
without duplications from the perspectives of both the CFO (Figures 9a and 9c respectively) and the 
CIO (Figures 9b and 9d respectively). The axes of both figures show the level, in percentage terms, of 
risk R1 and R2 obtained by the 31 laboratories in the two initial fuzzy subsystems, while the area of the 
circles represents the level of global risk R3 for each laboratory. Moreover, for the purposes of better 
visualization, the risk level of each laboratory (circle) has been associated to a color scale that ranges 
from bright green (low global innovation risk) to bright red (high global innovation risk) through a range 
of oranges (intermediate innovation risk). 
Figures 9a and 9c illustrate how an increase in the level of risk R1 translates into a more significant 
increment in global risk when seen from the CFO perspective. From this viewpoint, for the period of 
analysis that we consider, the firms with lower global innovation risk are Merck, Glaxosmithkline, and 
Novartis, while the laboratories with higher global innovation risk are Medicines Company, Orion, and 
Regeneron. On the other hand, global innovation risk is more sensitive to an increase in the level of risk 
R2 from the perspective of the CIO, as can be seen in Figures 9b and 9d. In this case, the pharmaceutical 
firms with lower global risk are Allergan, Merck, and J&J, while those with higher global risk are 
MedicinesCompany / Regeneron (the former if we consider duplications, the latter if we do not), UCB, 
and Celgene.  
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a) Innovation Risk from the CFO perspective (without CT duplications) 
Note. CFO stands for Chief Financial Officer. CT without duplications imply that we consider only the main indication (targeted 
disease) of each clinical trial. R1 and R2 are the two dimensions of innovation risk. See Figure 1. 
 
 
b) Innovation Risk from the CIO perspective (without CT duplications) 
Note. CIO stands for Chief Innovation Officer. CT without duplications imply that we consider only the main indication 
(targeted disease) of each clinical trial. R1 and R2 are the two dimensions of innovation risk. See Figure 1. 
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c) Innovation Risk from the CFO perspective (with CT duplications) 
Note. CFO stands for Chief Financial Officer. CT with duplications imply that we consider a maximum of six main indications 
(targeted diseases) that are being targeted simultaneously by a given clinical trial.R1 and R2 are the two dimensions of 
innovation risk. See Figure 1.  
 
 
d) Innovation Risk from the CIO perspective (with CT duplications) 
Note. CIO stands for Chief Innovation Officer. CT with duplications imply that we consider a maximum of six main indications 
(targeted diseases) that are being targeted simultaneously by a given clinical trial.R1 and R2 are the two dimensions of 
innovation risk.. R1 and R2 are the two dimensions of innovation risk. See Figure 1. 
Figure 9. Global Innovation Risk of the 31 pharmaceutical laboratories analyzed. 
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Figure B.1, in Appendix B, shows the R1 and R2 risks for the pharmaceutical laboratories that we cover 
in this research work.   
Regarding the interpretation and possible alternative ways of using our evaluation model and our results 
(shown in the two-dimensional graphs of our third FIS), the reader should bear in mind that we include 
financial information in the first FIS (R&D expenditure and financial transactions) and pipeline risk 
information in the second FIS (probabilities of success of both new authorized molecules and clinical 
trials). Given our four inputs in the model, we are not in a position to use new chemical entities (NCEs) 
and clinical trials (CTs) as drug pipeline data in order to evaluate the third FIS (nor can we use R&D 
expenditure and the number of announced financial transactions per lab (NFTs) to evaluate this third 
fuzzy subsystem).  
Augusiak et al. (2014) coin the term “evaludation”, merging the concepts of validation and evaluation. 
Evaluation is a more neutral term than validation. They consider six elements of “evaluation” in their 
modelling cycle1 that we have followed in order to be systematic when evaluating our model.  
In order to evaluate our model, we showed our graphs to the same experts in the pharmaceutical field 
that helped us to establish the rules of the model to request their impressions regarding its results2. 
Special attention was given to the comments, insights and impressions given by the expert from a large 
pharmaceutical laboratory (whose company is not part of our sample of pharmaceutical laboratories). 
These experts indicate that, with our model, it is possible to compare firms with high risk that are located 
in different regions of the bi-dimensional risk graph. For example, Celgene is a risky laboratory with 
higher CFO risk than Regeneron while Regeneron has a higher CIO risk than Celgene. Celgene is more 
oriented towards rare diseases and diseases with higher pipeline risk but it has a sounder financial 
position than Regeneron which is a smaller biotech lab.  
 
1 We follow the modelling cycle specified by Augusiak et al. (2014). Given our sources, we are sure about the quality of our 
data, and we think that our four inputs capture innovation risk in a simple but effective manner. Our equations and the fuzzy 
software are valid in our approach. Regarding model analysis, we explore sensitivity to changes in parameters considering CTs 
with and without duplications. Regarding model output corroboration, we contacted experts in order to share our output results 
and also ran regressions including new data that were not used during the development of our model and model parametrisation.  
2 Regarding the construction of the rules of the model, we combined our own experience in the pharmaceutical field with the 
expertise of outside experts. In particular, we contacted a person from a pharmaceutical laboratory that it is not in our sample 
and a person with a PhD in Biochemistry with no current links to any pharmaceutical laboratory and no conflict of interest 
regarding our study. 
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With the aim of evaluating our model using different approaches, we identified some additional 
variables that were not used in our fuzzy model and are useful for evaluating our model results.  
We ran a series of Ordinary Least Squares (OLS) regressions with bootstrap (500 replications) robust 
standard errors that we show in Appendix C, where the dependent variable is a variable that was not 
used as an input in the fuzzy model but may be related to innovation risk, such as sales or debt3. We use 
instrumental variables in order to better account for endogeneity and causality issues. See also the 
correlation matrix in Table 4. 
Table 4. Correlation matrix.  
 Avg Sales Sales Rat. Avg Debt Debt Rat. Avg Ta. Avg MCap 
Avg Sales 1.0000 - - - - - 
Sales Rat. -0.2361 1.0000 - - - - 
Avg Debt 0.8654 -0.3768 1.0000 - - - 
Debt Rat. 0.2708 -0.2278 0.5388 1.0000 - - 
Avg Ta. 0.9144 -0.4457 0.8871 0.2015 1.0000 - 
Avg MCap 0.8893 -0.3317 0.7636 0.1754 0.8889 1.0000 
Note. The average of each variable is calculated in the period 2008 to 2013 which is the same time period that is used in order 
to calculate innovation risk. Avg Sales are average sales of each pharmaceutical laboratory in the period 2008 to 2013. Sales  
Rat. is the ratio of sales to total assets in the same period. Avg Debt is the average debt while Debt Rat. is the ratio of debt to 
total assets. Avg Ta. is average total assets and Avg Mcap is the average market capitalization in the period 2008 to 2013. See 
appendix C for additional regressions using lagged values as instruments. 
Regarding sales, the following Table 5 shows OLS results where average sales (or average sales to total 
assets in the period) are the dependent variable and CFO and CIO innovation risk are the two 
independent variables. CFO innovation risk is significant at the 1% level when the dependent variable 
is average sales in the period 2008 to 2013, but CIO innovation risk is not significant. The coefficient 
of CFO is negative although very close to zero. When the dependent variable is the ratio of sales to total 
assets in the period 2008 to 2013, CFO innovation risk is significant at the 10% level but CIO innovation 
risk is not significant. The coefficient of CFO is positive in this case. Thus, after adjusting for size 
(dividing by average total assets), the coefficient changes. 
 
3 We consider average sales in the period 2008 to 2013 as well as the ratio of sales in the period to average total assets in the 
period. We also consider average debt in the period as well as the ratio of average debt to average total assets in the period. 
The variable of sales (or debt) also captures the size of the pharmaceutical laboratory. In order to adjust for size, we divide 
sales (or debt) by average total assets in the period.   
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Regarding debt, Table 6 shows OLS results where average debt (or average debt to total assets over the 
period) is the dependent variable and CFO and CIO innovation risk are the independent variables. CFO 
innovation risk is significant at the 1% level when the dependent variable is average debt in the period 
2008-2013, and CIO innovation risk is significant at the 10% level. The CFO coefficient is negative and 
the CIO coefficient is positive, both being very close to 0. When the dependent variable is the ratio of 
debt to total assets in the period 2008 to 2013, CFO innovation risk is significant at the 10% level but 
CIO innovation risk is not significant. The CFO coefficient is negative in this case. Thus, after adjusting 
for size (dividing by average total assets), the coefficient does not change. Given our results, more debt 
(a higher debt ratio) is associated with lower innovation risk (or vice-versa, as we are not inferring 
causality, see Appendix C).     
By using OLS regressions we tried to assess the relevance of innovation risk for explaining debt (ratio) 
in Table 6, and also for explaining sales (ratio) in Table 5. We also ran additional regressions with total 
assets (or market capitalization). Results are similar to those in columns (i) and (ii) of Tables 5 and 6. 
This is not surprising, given that average sales, average debt, average total assets and average market 
capitalization are different proxies for size. See Appendix C for further regressions with instruments 
(lagged values) to better account for endogeneity issues. 
One alternative approach to further evaluate and/or validate our model may be to use additional public 
and/or private (proprietary data) from the laboratories in our sample.  
Though the methodology is applied to 31 large pharmaceutical laboratories, it is also applicable to, and 
valid for, other pharmaceutical laboratories. The sample of 31 large pharmaceutical firms comes from 
the sample of 37 laboratories in Gascón et al. (2017). The overall risk results offered by our Inference 
System in these 31 laboratories can be seen in Table D.1 (Appendix D) (outputs of the third fuzzy 
subsystems both with and without duplications in the CTs).  
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Table 5. Summary of the results of the regression models with sales as the dependent variable. 
 Avg Sales (i) 
CT dup  
Avg Sales (ii) 
CT no dup  
Sales ratio (iii) 
CT dup 
Sales ratio (iv) 
CT no dup 
CFO CT dup -1.14e+08*** 
(2.04e+07) 
 .612*  
(0.342) 
 
CIO CT dup 2.89e+07 
(2.94e+07) 
 -0.542  
(0.363) 
 
CFO CT nodup  -1.14e+08*** 
(1.98e+07) 
 0.622* 
(0.332) 
CIO CT nodup  3.01e+07 
(3.22e+07) 
 -0.532 
(0.326) 
Constant 7.87e+07*** 
(1.61e+07) 
7.80e+07*** 
(1.45e+07) 
0.537*** 
 (0.193) 
0.519*** (0.177) 
R-squared 0.489 0.493 0.135 0.134 
No. observations 31 31 31 31 
Note. The dependent variable in each regression is average sales in (i) and (ii) and the ratio of sales to total assets in (iii) and 
(iv). CFO CT dup and CIO CT dup are the CFO and CIO perspectives with CT duplications.  CFO CT nodup and CIO CT 
nodup are the CFO and CIO perspectives without CT duplications. All variables (innovation risk as well as sales and sales 
ratio) are calculated in the period 2008 to 2013. See appendix C for additional regressions using lagged values of sales. In 
addition, *, **, *** indicate significance at the 1, 5 and 10% levels. Bootstrap Standard errors in parentheses. 
 
Table 6. Summary of the results of the regression models with debt as the dependent variable. 
 Avg Debt (i) 
CT dup  
Avg Debt (ii) 
CT no dup  
Debt ratio (iii) 
CT dup 
Debt ratio (iv) 
CT no dup 
CFO CT dup -5.78e+07*** 
(9.95e+06) 
 -0.363*  
(0.205) 
 
CIO CT dup 3.14e+07* 
(1.63e+07) 
 0.365 
(0.236) 
 
CFO CT nodup  -5.68e+07*** 
(9.82e+06) 
 -0.344* 
(0.204) 
CIO CT nodup  2.96e+07* 
(1.75e+07) 
 0.325 
(0.227) 
Constant 2.75e+07*** 
(6.66e+07) 
2.82e+07*** 
(6.99e+07) 
0.208* 
 (0.109) 
0.224** 
(0.105) 
R-squared 0.429 0.420 0.149 0.123 
No. observations 31 31 31 31 
Note: The dependent variable in each regression is average debt in (i) and (ii) and the ratio of debt to total assets in (iii) and 
(iv). CFO CT dup and CIO CT dup are the CFO and CIO perspectives with CT duplications.  CFO CT nodup and CIO CT 
nodup are the CFO and CIO perspectives without CT duplications. All variables (innovation risk as well as debt and debt ratio) 
are calculated in the period 2008 to 2013. See appendix C for additional regressions using lagged values of debt. In addition, 
*, **, *** indicate significance at the 1, 5 and 10% levels. Bootstrap Standard errors in parentheses. 
 
Preprint – Article accepted by Artificial Intelligence in Medicine https://doi.org/10.1016/j.artmed.2019.101703 
 32 
5. Conclusions 
Our fuzzy evaluation model can be interpreted as a useful tool to evaluate the impact of a portfolio of 
“local” decisions, i.e. at an individual trial level, on the “global” innovation risk, i.e. considering the 
whole organisation. In this sense, it allows decision makers to evaluate their potential, or future, 
innovation risk under different strategies; thus allowing for beneficial what-if analyses of how 
innovation risk is affected by strategic changes in the portfolio of clinical trials. This information would 
help managers at different decision levels take better strategic decisions regarding the management of 
their present and future portfolio of clinical trials in an uncertain environment, in the profit of not only 
themselves but also the wider healthcare industry. In summary, our fuzzy model enhances strategic 
decision making at pharma labs by comparing the present innovation risk scenario of a pharma lab 
relative to its competitors (embedding knowledge based on a given portfolio of clinical trials, on prior 
success and on a given R&D budget). In addition, managers will better understand what would happen 
in the long term to the pharma lab innovation risk if alternative strategic changes in the portfolio of 
clinical trials are proposed or implemented. 
We would like to note that our fuzzy evaluation model assess innovation risk at large pharmaceutical 
laboratories by integrating information from different publicly available sources. For this reason, given 
that we provide the necessary tools and datasets, new analyses can be easily performed. Also, this model 
provides a framework that is useful to explore and provide valuable insights on the link between R&D 
strategy and innovation risk at pharmaceutical companies. 
The application of fuzzy methodologies to the healthcare industries has been proposed recently by 
several authors. For example, Albino et al. (2018) and Nakawala et al. (2018) employ this approach to 
improve process and enhance training at hospitals. A different line of research is that by Carlsson et al. 
(2007) and Lo Nigro et al. (2016), which suggest the usefulness of fuzzy techniques to optimize the 
R&D portfolio. Guo et al. (2018) highlight that it is fundamental to appropriately balance strategic and 
financial issues when figuring the composition of the R&D portfolio in a pharmaceutical laboratory. 
They combine fuzzy techniques with a real options approach. In order to validate the model with a real 
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case, they apply it to a single, relatively small and unknown Chinese pharmaceutical company, which 
every year selects a specific number of projects (around 30) to implement from 100 candidate projects. 
In this paper, after consulting experts in the field with different profiles, we develop a fuzzy evaluation 
model that helps managers at R&D intensive pharmaceutical laboratories take strategic decisions by 
capturing the innovation risk of the R&D portfolio of clinical trials. Our approach allow them to 
compare the innovation risk of a specific laboratory with the innovation risk of competitors. It also 
enables managers to visualize simultaneously the financial and strategic sides of innovation risk. The 
model that we propose in this work is based on an innovative 2-tuple method, which allows to reach an 
agreement in both the fuzzy labels of the partitions of the relevant variables and the rules embedded in 
the knowledge bases, according to the judgment made by experts. Thus, our results seem compatible 
with our experts’ view of what innovation risk at large pharmaceutical laboratories entails, and we 
provide all the necessary tools, files and datasets to replicate our results or to extend our fuzzy model. 
From this perspective, we contribute to existing literature regarding innovation risk by capturing both 
success and failure when managing the drug pipeline. Our new 2-tuple method fuzzy methodological 
approach combines experts’ knowledge from different fields with a variety of public datasets in a novel 
way. Therefore, our approach is novel in terms of the fuzzy method and in terms of the way we embed 
knowledge from different expert profiles and different datasets although it is based on previous 
contributions. 
It should be highlighted that FIS have been proposed for decision making when managers are faced with 
complex and risky environments and the dataset is small but has many attributes (Li et al., 2011). In 
addition, risk issues are very relevant in deterring decision makers from expanding in the generic 
pharmaceutical business (Puente et al., 2011).  
With the aim of determining whether a laboratory has a higher or lower innovation risk relative to other 
laboratories, we consider four input variables in two fuzzy subsystems (R&D expenditure, announced 
financial transactions, probabilities of success of authorized New Chemical Entities (NCEs) and 
probabilities of success of Clinical Trials (CTs)). The first fuzzy subsystem captures the financial side 
of innovation risk while the second one captures the pipeline side. 
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In our paper, innovation risk comparisons are made and graphical surfaces are analyzed in order to 
interpret the results. Correct application of this type of evaluation model requires that experts in the field 
devote enough time and effort to generating the knowledge base. Otherwise, the system would yield 
misleading results. We seek the evaluation of our model by sharing our graphical surfaces results with 
experts in the field who gave their insights about the feasibility and usefulness of our fuzzy model 
outcome and by running regressions where innovation risk is related to variables such as laboratory sales 
and debt. In section 4, our regressions suggest a negative and significant relationship between sales (or 
debt) and CFO innovation risk. Both sales and debt also capture the size effect. We also run additional 
regressions using a sales ratio and a debt ratio. We find a positive relationship between the sales ratio 
and CFO innovation risk, and a negative relationship between the debt ratio and CFO innovation risk. 
Also, CIO innovation risk is significant at the 10% level when the dependent variable is average debt. 
We perform additional robustness tests with lagged values of sales and debt (as instruments) in 
Appendix C. 
The results of our evaluation model have been discussed with experts in order to evaluate the model and 
determine its usefulness for analyzing innovation risk, given the strategic choices of the 31 large 
pharmaceutical laboratories in our sample. It is also valid for carrying out a systematic analysis of 
innovation risk in other laboratories outside our sample. We provide all the necessary tools, files and 
data to replicate our results or to apply our new fuzzy model to a combination of different datasets. 
Regarding possible extensions of our proposed methodology, small pharmaceutical laboratories are a 
relevant part of the pharmaceutical picture but are not covered in this paper (Schuhmacher et al. 2016; 
Macher and Boerner 2012) and advances in computational power are changing the way small labs may 
compete (Jamali et al. 2016). Wong et al. (2018) claim that previous estimates of drug development 
success rates, such as those by Thomas et al. (2016), rely on small databases that are not publicly 
available and may be subject to potential biases. In any case, it would be possible to re-estimate 
innovation risk at large pharma labs using the new estimates by Wong et al (2018).  
When it comes to potential extensions related to the proposed fuzzy methodology, it would be possible 
to deepen in the establishment of consensus among experts in the relevant area. Thus, some restrictions 
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imposed in this work could be relaxed, allowing each expert to evaluate the model variables by 
proposing their own partitions independently of the rest of the evaluators (both in terms of the number 
of labels assigned to each variable and their parameterization) -see Herrera et al. (2000)-. 
Other promising approaches for studying drug portfolio management and/or quantifying innovation risk 
may be based on simulation (Blau et al., 2004; Perez-Escobedo et al., 2011; Yu, 2012; Perez-Escobedo 
et al., 2012; Rosiello et al.. 2013), optimization (George and Farid 2008a; 2008b; Colvin and Maravelias, 
2011; Laínez et al., 2012; Luo, 2012; Gibbert et al., 2014), real options (Bergemann and Hege, 1998; 
2005; Ewens and Fons-Rosen, 2013; Ewens et al., 2014; Kerr and Nanda, 2015) and a combination of 
fuzzy and real options (Carlsson et al., 2007;  Lo Nigro et al., 2016; Guo et al., 2018) or other related 
methodologies, sometimes mixing more than one methodology at a time. Irrespective of the actual 
methodology(ies) used, it is interesting to study the strategic choices faced by large pharmaceutical 
laboratories when trying to manage innovation risk and compete with both large and small laboratories. 
Finally, in this paper, we do not take into account time to approval, as in Macher and Boerner (2012) 
and Garzón-Vico et al. (2016), which may be an additional worth considering. 
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Appendix A. Data. 
Table A.1. Sources of data for the construction of inputs. 
Input (factor) Definition Source Comments 
R&D Average expenditure per 
pharmaceutical 
laboratory in R&D from 
2008 to 2013 
Gascón et al. (2017).  Table 
12. Variable: I3-IRD 
In Gascón et al. (2017) there are 37 laboratories in the sample. In our final sample there are 31. The 
following laboratories were removed from the initial sample: Celltrion, CSL, Hospira, Meda AB and 
Mitsubishi. Also, Merck KGAA and Merck & Co. data were merged because some CTs were not 
easy to classify between the two Mercks. 
NFTs Number of financial 
transactions per 
pharmaceutical 
laboratory from 2008 to 
2013 
Gascón et al. (2017). Table 6. 
Variable: Number of 
announced transactions 
In Gascón et al. (2017) there are 37 laboratories in the sample. In our final sample there are 31. Table 
6 contains information on the number of transactions (NFTs) and on the accumulated size of 
transactions. Both measures were considered although, in this paper, we only report the model with 
NFTs. 
NCEs x Prob Probabilities of success 
per ATC from Phase I to 
approval of New 
Chemical Entities 
authorized by EMA and 
FDA per pharmaceutical 
laboratory from 2008 to 
2013 
Authorized NCEs: Websites 
of the European Medicines 
Agency (EMA) and the Food 
and Drug Administration 
(FDA).  
Probabilities of success per 
ATC from Phase I to 
approval: Thomas et al. 
(2016) 
Information on NCEs authorized by EMA and FDA per ATC code is combined with information on 
the probability of success per ATC from Phase I to Approval. 
Thomas et al. (2016) probabilities are specific to the biotech sector from 2006 to 2015 and we use 
these probabilities as a proxy for our sample of large pharmaceutical laboratories. Thus, we are 
assuming that all laboratories in our sample have the same probabilities of success when targeting a 
given disease covered by a given ATC code. 
Thomas et al. (2016) provide probabilities for 16 disease areas. With the aid of an expert in 
biochemistry, we converted these 16 disease areas into ATC codes in order to merge data from 
different sources (See Table A.2). 
CTs x Prob Probabilities of success 
per ATC from the 
corresponding phase (I, 
II, III and IV) of each CT 
to approval per 
pharmaceutical 
CTs: Clinicaltrials.gov 
website 
Probabilities of success per 
ATC from the corresponding 
phase (I, II, III and IV) of the 
Information on CTs per ATC code is combined with information on the probability of success per 
ATC from the corresponding pipeline phase of the CT to Approval. 
Information on CTs in Clinicaltrials.gov is classified, at the aggregate level, into 25 different 
conditions (disease areas). With the aid of an expert in biochemistry, we converted these 25 disease 
areas into ATC codes in order to merge data from different sources (See Table A.4 for details about 
expert associations that link CTs conditions to ATC codes).  
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laboratory with starting 
date from 2008 to 2013 
CT to approval: Thomas et 
al. (2016) 
 
Moreover, CTs in Clinicaltrials.gov are reported at the sub-condition level (very detailed disease 
area). As of February 2017, there was a list that contained 6,232 sub-conditions (with some 
duplications because sometimes a given sub-condition belongs to more than one condition). For 
example, the sub-condition “Pain” belongs to two disease areas (Nervous system diseases and 
Symptoms and General Pathology) or the sub-condition “Digestive System Neoplasms” belongs to 
two disease areas (Cancers and Other Neoplasms and Digestive System Diseases). 
For our sample of 31 laboratories, we had to convert the sub-condition of each CT into a condition 
(disease area). Each CT may target more than one sub-condition and 99% of the CTs in our sample 
target six sub-conditions or less. We considered only the first six sub-conditions and we dropped the 
remaining sub-conditions of each CT (only 1% of the CTs targeted more than six sub-conditions). 
See Table A.7 for summary statistics and information on the exact matching procedure (exactly 
identified CTs with and without duplications). We ended up with two databases of CTs (one with 
perfectly identified sub-conditions with duplications, and another with no duplications).  
We combine condition (disease area converted into ATC codes) with Thomas et al. (2016) success 
probabilities from the corresponding phase to approval. See Table A.8 for summary statistics 
regarding CTs per phase. 
See Table A.5 for a description of the associations of clinicaltrial.gov conditions (disease areas) with 
ATC codes and to success probabilities in different pipeline phases from Thomas et al. (2016). 
Thomas et al. (2016) probabilities are specific to the biotech sector from 2006 to 2015. See previous 
comments in the NCEs x Prob factor.   
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Table A.2. Estimated probabilities of success of authorized NCEs from phase I to Approval. 
ATC ATC Contents Disease 
Thomas et al. (2016) 
(i) Phase I to 
Approval 
Thomas et al. (2016) 
(ii) Start 
equivalent 
A Alimentary 
tract and metabolism 
Metabolic 15.3% 6.54 
B Blood and blood forming 
organs 
Hematology 26.1% 3.83 
C Cardiovascular system Cardiovascular 6.6% 15.15 
D Dermatologicals Other 16.3% 6.13 
G Genito-urinary 
system and sex hormones 
Urology 11.4% 8.77 
H Systemic hormonal preparatio
ns, excluding sex hormones 
and insulins 
Endocrine 13.2% 7.58 
J Antiinfectives for systemic 
use 
Infectious disease 19.1% 5.24 
L Antineoplastic and immune-
modulating agents 
Oncology 5.1% 19.61 
M Musculo-skeletal system Other 16.3% 6.13 
N Nervous system Neurology 8.4% 11.90 
P Antiparasitic products, insecti
cides and repellents 
Other 16.3% 6.13 
R Respiratory system Respiratory 12.8% 7.81 
S Sensory organs Ophthalmology 17.1% 5.85 
V Various Other 16.3% 6.13 
Note. This table combines information on 1) ATC codes and 2) Phase I to Approval probabilities of success from Thomas et 
al. (2016). With the aid of an expert in biochemistry, we converted disease areas from Thomas et al. (2016) into ATC codes. 
When a clear association between a given disease area and an ATC code did not exist, the probability associated with “other” 
diseases (16.30%) was used. Information on probabilities from phase I to approval may be interpreted using the start-equivalent 
approach. That is to say, for ATC code A, the probability in column (i) is 15.3% which implies in column (ii) that 6.54 new 
ATC-code A drugs are needed at the starting point (phase I) in order to obtain, on average, an authorized NCE in this ATC 
code.   
Table A.3. Authorized NCEs per pharmaceutical laboratory and average probabilities of success of NCEs adjusting for ATC 
codes. 
Lab 
Number 
Laboratory (i) NCEs 
authorized 
per Lab 
(ii) Sum of 
Probabilities  
(iii) NCEs x Prob 
1 ABBOTT 1 0.066 6.60% 
2 ALLERGAN 1 0.191 19.10% 
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3 AMGEN 5 1.011 20.22% 
4 ASTELLAS 7 0.695 9.93% 
5 ASTRAZENECA 10 1.663 16.63% 
6 BAYER 10 1.366 13.66% 
7 BIOGEN 2 0.168 8.40% 
8 BRISTOL 8 1.14 14.25% 
9 CELGENE 6 0.446 7.43% 
10 EISAI 7 0.591 8.44% 
11 ELI LILLY 5 0.883 17.66% 
12 GILEAD 7 1.309 18.70% 
13 GLAXOSMITHKLINE 27 3.345 12.39% 
14 H.LUNDBECK 4 0.405 10.13% 
15 IPSEN 1 0.163 16.30% 
16 J&J 6 1.038 17.30% 
17 MEDICINES COMPANY 1 0.066 6.60% 
18 MERCK^2 16 2.205 13.78% 
19 NOVARTIS 40 4.376 10.94% 
20 NOVO NORDISK 6 1.134 18.90% 
21 ORION 4 0.336 8.40% 
22 OTSUKA 3 0.216 7.20% 
23 PFIZER 15 1.46 9.73% 
24 REGENERON 3 0.273 9.10% 
25 RICHTER 1 0.114 11.40% 
26 ROCHE 9 0.459 5.10% 
27 SANOFI 18 2.38 13.22% 
28 SHIRE 5 0.591 11.82% 
29 TAKEDA 21 2.761 13.15% 
30 TEVA 5 0.681 13.62% 
31 UCB 4 0.27 6.75% 
 TOTAL  258 31.802 12.33% * 
Note. This table combines information on authorized NCEs at the ATC code level from our sample of 31 laboratories in the 
period 2008-2013 with information on success probabilities from Phase I to Approval from Thomas et al. (2016).  Column (i) 
contains the number of authorized NCEs per lab. Column (ii) is the sum of probabilities, adjusting for the ATC code of each 
authorized NCE, per lab. Our input variable 3, NCEs x Prob, is calculated in Column (iii) which is equal to column (ii) divided 
by column (i). Thus, column (iii) contains the average probability of success per laboratory based on authorized NCEs adjusting 
for ATC code. On average the laboratories in our sample have a 12.33% probability of success (FDA or EMA approval) when 
they start researching at Phase I, based on authorized NCEs. See also Table I for a more detailed description of the calculation 
of the NCEs x Prob variable in column (iii). 
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Table A.4. Association of Clinicaltrials.gov conditions (disease areas) to ATC codes. 
ATC Condition number 
(disease area number) 
Condition description (disease description) 
J 1 Bacterial and Fungal Diseases   
N 2 Behaviors and Mental Disorders   
B 3 Blood and Lymph Conditions   
L 4 Cancers and Other Neoplasms   
A 5 Digestive System Diseases   
V 6 Diseases and Abnormalities at or before Birth   
V 7 Disorders of Environmental Origin   
S 8 Ear, Nose, and Throat Diseases   
S 9 Eye Diseases   
H 10 Gland and Hormone Related Diseases   
C 11 Heart and Blood Diseases   
L 12 Immune System Diseases   
V 13 Mouth and Tooth Diseases   
M 14 Muscle, Bone, and Cartilage Diseases   
N 15 Nervous System Diseases   
A 16 Nutritional and Metabolic Diseases   
V 17 Occupational Diseases   
P 18 Parasitic Diseases   
R 19 Respiratory Tract (Lung and Bronchial) Diseases   
D 20 Skin and Connective Tissue Diseases   
V 21 Substance Related Disorders   
V 22 Symptoms and General Pathology   
G 23 Urinary Tract, Sexual Organs, and Pregnancy Conditions   
J 24 Viral Diseases   
V 25 Wounds and Injuries   
Note. This table combines information on 1) ATC Codes and 2) CTs conditions (25 disease areas) from Clinicaltrials.gov. With 
the aid of an expert in biochemistry, we converted CTs disease areas (conditions) from Clinicaltrials.gov into ATC codes. 
When a clear association between a disease area and an ATC code did not exist, the ATC V (various) was associated with the 
corresponding CTs disease area (condition). 
 
 
Table A.5. Association of Clinicaltrials.gov conditions (disease areas) to ATC codes and to phase I to phase IV probabilities. 
Condition 
number 
(Disease area) 
ATC Disease 
Thomas et al. (2016) 
 
Phase I to 
Approval 
Phase II to 
Approval 
Phase III to 
Approval 
NDA/BLA 
to Approval 
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1 J Infectious disease 19.10% 27.50% 64.50% 88.70% 
2 N Neurology 8.40% 14.20% 47.80% 83.20% 
3 B Hematology 26.10% 35.70% 63.00% 84.00% 
4 L Oncology 5.10% 8.10% 33.00% 82.40% 
5 A Metabolic 15.30% 25.10% 55.50% 77.80% 
6 V Other 16.30% 24.40% 61.50% 88.40% 
7 V Other 16.30% 24.40% 61.50% 88.40% 
8 S Ophthalmology 17.10% 20.20% 45.20% 77.50% 
9 S Ophthalmology 17.10% 20.20% 45.20% 77.50% 
10 H Endocrine 13.20% 22.40% 55.90% 86.00% 
11 C Cardiovascular 6.60% 11.30% 46.70% 84.20% 
12 L Oncology 5.10% 8.10% 33.00% 82.40% 
13 V Other 16.30% 24.40% 61.50% 88.40% 
14 M Other 16.30% 24.40% 61.50% 88.40% 
15 N Neurology 8.40% 14.20% 47.80% 83.20% 
16 A Metabolic 15.30% 25.10% 55.50% 77.80% 
17 V Other 16.30% 24.40% 61.50% 88.40% 
18 P Other 16.30% 24.40% 61.50% 88.40% 
19 R Respiratory 12.80% 19.60% 67.30% 94.60% 
20 D Other 16.30% 24.40% 61.50% 88.40% 
21 V Other 16.30% 24.40% 61.50% 88.40% 
22 V Other 16.30% 24.40% 61.50% 88.40% 
23 G Urology 11.40% 20.00% 61.20% 85.70% 
24 J Infectious disease 19.10% 27.50% 64.50% 88.70% 
25 V Other 16.30% 24.40% 61.50% 88.40% 
Note. This table combines information on 1) ATC Codes, 2) Clinicaltrials.gov conditions (25 disease areas) and 3) Probabilities 
of success from the corresponding phase of the CT to approval, from Thomas et al. (2016). These are the probabilities that we 
use when assessing the probability of success of a CT in a given pipeline phase.  With the aid of an expert in biochemistry, we 
converted both CTs disease areas (conditions) from Clinicaltrials.gov and diseases from Thomas et al. (2016) into ATC codes. 
When a clear association did not exist, the ATC V (various) and/or the “other” disease was associated with the corresponding 
CTs disease area (condition) and probability. We interpret the probability of success from NDA/BLA to Approval as the 
probability of success from Phase IV to approval. New Drug Application (NDA) and Biologic License Application (BLA) 
probabilities. 
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Table A.6. CTs per pharmaceutical laboratory and average probabilities of success of NCEs adjusting for ATC codes and pipeline phase (with and without duplications). 
  (i) (ii) No duplications (iii) (iv) (v) Duplications (vi) 
Lab 
Number 
Laboratory Sum of   
Probabilities 
Number  
of CTs 
CTs x Prob Sum of  
 Probabilities 
Number  
of CTs 
CTs x Prob 
1 ABBOTT 57.72 127 45.45% 91.10 210 43.38% 
2 ALLERGAN 70.14 129 54.37% 96.69 182 53.13% 
3 AMGEM 30.76 93 33.08% 38.87 131 29.67% 
4 ASTELLAS 53.84 108 49.85% 83.75 167 50.15% 
5 ASTRAZENECA 71.18 191 37.27% 100.65 290 34.71% 
6 BAYER 83.40 220 37.91% 129.06 337 38.30% 
7 BIOGEN 13.46 36 37.40% 25.95 71 36.54% 
8 BRISTOL 133.04 355 37.48% 222.01 585 37.95% 
9 CELGENE 31.61 158 20.00% 78.04 414 18.85% 
10 EISAI 16.17 41 39.44% 21.45 57 37.63% 
11 ELI LILLY 104.81 279 37.57% 178.04 484 36.79% 
12 GILEAD 49.54 121 40.95% 92.77 231 40.16% 
13 GLAXOSMITHKLINE 270.38 790 34.23% 404.16 1220 33.13% 
14 H. LUNDBECK 10.90 27 40.37% 12.70 30 42.35% 
15 IPSEN 5.72 14 40.84% 11.22 29 38.71% 
16 J&J 136.36 267 51.07% 228.90 486 47.10% 
17 MEDICINES COMPANY 217.53 549 39.62% 330.48 878 37.64% 
18 MERCK^2 206.82 510 40.55% 317.01 816 38.85% 
19 NOVARTIS 189.42 482 39.30% 305.30 794 38.45% 
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20 NOVONORDISK 79.99 201 39.79% 165.75 432 38.37% 
21 ORION 10.98 27 40.66% 17.08 49 34.85% 
22 OTSUKA 35.27 86 41.01% 46.38 126 36.81% 
23 PFIZER 207.87 566 36.73% 330.45 925 35.72% 
24 REGENERON 18.16 53 34.27% 25.70 75 34.26% 
25 RICHTER 4.28 10 42.79% 4.68 13 35.97% 
26 ROCHE 91.84 214 42.92% 159.33 387 41.17% 
27 SANOFI 175.97 364 48.34% 269.75 558 48.34% 
28 SHIRE 21.20 47 45.10% 38.06 88 43.25% 
29 TAKEDA 43.70 92 47.50% 64.58 131 49.30% 
30 TEVA 19.59 54 36.27% 38.44 107 35.92% 
31 UCB 24.85 76 32.70% 34.07 111 30.69% 
 Total 2486.5 6287 39.55% 3962.4 10414 38.05% 
Note. This table combines information on CTs at the ATC code level from our sample of 31 laboratories in the period 2008-2013 with information on success probabilities from the corresponding 
phase (I to IV) to Approval from Thomas et al. (2016), with and without duplications in the CTs (see comments in Table A.1 regarding CTs). Column (i) contains the sum of probabilities from the 
corresponding phase to approval (adjusting for ATC code). Column (ii) is the number of CTs per lab. Our input variable 4 is CTs x Prob which is calculated (with no CT duplications) in Column 
(iii), which is equal to column (i) divided by column (ii). Thus, column (iii) contains the average probability of success per laboratory based on CTs adjusting for phase and for ATC code. On 
average the laboratories in our sample have a 39.55% probability of success in their average CT and their average phase. See also Table A.1 for a more detailed description of calculation of the 
CTs x Prob variable in column (iii). In the case of CT duplications, our input variable 4 is again CTs x Prob although it is calculated in Column (vi). For more information regarding the calculation 
of probabilities with and without duplications, see also Table A.7. 
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Table A.7. Exactly identified CTs per step (COND1 to COND 6).  
COND (i) Exactly identified CTs 
(without duplications) 
(ii) Exactly identified CTs 
(with duplications) 
COND1 5487 9025 
COND2 664 1168 
COND3 88 138 
COND4 24 41 
COND5 15 24 
COND6 9 18 
Total 6287 10414 
Note. In order to identify the condition (disease area) of each CT in our final sample, we imposed an exact match between the 
sub-condition of the CT and a sub-condition from the list of 6,232 sub-conditions.  In an iterative way, in a first step, we 
searched for an exact match in the first sub-condition of each CT (COND1). A total of 5,487 CTs, with no duplications, column 
(i), were identified. We added these 5,487 CTs with an exact match in COND1 to our final sample of CTs. With the remaining 
CTs with no perfect match, in a second step, we searched for an exact match in the second sub-condition of each remaining CT 
(COND2) for the CTs targeting two sub-conditions or more. We also added these 664 CTs with an exact match in COND2 and 
no duplications to our final sample of CTs. With the remaining CTs, we followed a similar procedure for COND3, COND4, 
COND5 and COND6 (until we reached our sixth and last sub-condition). Our final sample of CTs has 6,287 CTs with no 
duplications. After completing these recurrent six steps, we had perfectly identified the condition of a total of 6,287 clinical 
trials, with no duplications, in our sample of 31 large pharmaceutical laboratories (see Table A.6) and, following a similar 
procedure, in column (ii), a total of 10,414 CTs, with duplications, in the same sample. See also comments in Table A.1 on 
CTs data. 
Table A.8.  Exactly identified CTs per pipeline phase. 
Pipeline Phases CTs per phase 
(without duplications) 
CTs per phase 
(with duplications) 
Early Phase 1 12 22 
Phase 1 1373 2319 
Phase 1|Phase 2 186 379 
Phase 2 1629 2827 
Phase 2|Phase 3 93 145 
Phase 3 1907 3078 
Phase 4 1087 1644 
Total 6287 10414 
Note. This table contains summary information regarding the distribution in our sample of CTs among pipeline phases. We use 
more detailed information from Thomas et al. (2016) in order to obtain the probabilities from the corresponding pipeline phase 
to approval at the ATC code level. See also comments in Table A.1. In the case of calculation of the probability from Early 
Phase 1 to approval in a given ATC, we decided to apply half the probability from phase I to approval. In the case of calculation 
of the probability from Phase 1|Phase 2 to approval in a given ATC, we decided to apply an average of the corresponding 
probabilities (from phase 1 to approval and from phase 2 to approval). In the case of calculation of the probability from Phase 
2|Phase 3 to approval in a given ATC, we decided to apply an average of the corresponding probabilities (from phase 2 to 
approval and from phase 3 to approval). 
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Appendix B. Risks R1 and R2 of the pharmaceutical laboratories.  
 
a) Risk R1 
 
b) Risk R2, without duplications 
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c) Risk R2, with duplications 
Figure B.1. Risks R1 and R2 of the 31 pharmaceutical laboratories analyzed. 
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Appendix C. OLS Robustness tests. Use of instruments in regressions. 
In order to run additional robustness tests, we chose innovation risk as the dependent variable4, given 
that we are in a position to use instruments when the independent variables are total assets, market 
capitalization, debt or sales. First, we included, as an independent variable, average total assets in the 
period 2008 to 2013 and in the period 2002 to 2007. The reason for calculating the average from 2002 
to 2007 is to use a lagged variable that may be a valid instrument in the case of endogeneity problems. 
With this instrument, we try to avoid endogeneity and causality problems in the estimates in the period 
2002 to 2007 although we also present results with independent variables in the period 2008 to 2013 
(see section 4).  
See correlation matrix of instruments in Table C.1. 
Table C.1. Correlation matrix of instruments (period 2002 to 2007). 
 Avg Sales Sales Rat. Avg Debt Debt Rat. Avg Ta. Avg MCap 
Avg Sales 1.0000 - - - - - 
Sales Rat. 0.1662 1.0000 - - - - 
Avg Debt 0.8591 0.0263 1.0000 - - - 
Debt Rat. 0.1543 -0.1757 0.4182 1.0000 - - 
Avg Ta. 0.9134 -0.0790 0.8598 0.0868 1.0000 - 
Avg MCap 0.8790 0.0703 0.6729 0.0548 0.8558 1.0000 
Note. The average of each variable is calculated in the period 2002 to 2007 in order to try to avoid possible spurious correlations 
between measures of innovation risk (calculated in the period 2008 to 2013) and explanatory variables (calculated in the period 
2002 to 2007). Avg Sales are average sales of each pharmaceutical laboratory in the period 2002 to 2007. Sales Rat. is the ratio 
of sales to total assets in the same period. Avg Debt is average debt while Debt Rat. is the ratio of debt to total assets. Avg Ta. 
is average total assets and Avg Mcap is average market capitalization in the period 2002 to 2007.  
Table C.2 contains four regressions where the dependent variable is one of the four measures of 
innovation risk calculated in the period 2008 to 2013 and, as instruments, we use two independent 
variables (average sales in the period 2002 to 2007 and average debt in the period 2002 to 2007).  With 
these (lagged values of variables sales and debt) instruments we try to avoid capturing spurious 
 
4 In section 4, we run OLS regressions where, for example, sales is the dependent variable and a measure of innovation risk is 
the independent variable. With this approach, we obtain a negative and significant relationship between sales and innovation 
risk. However, when using the same time period (2008 to 2013) for calculating innovation risk and average sales in the period, 
there are concerns regarding causality and, also, endogeneity issues may arise. In order to deal with these concerns, we run 
OLS regressions where the independent variable is average sales in the period 2002 to 2007 (in order to compare results, we 
also run the regression with contemporaneous sales in the period 2008 to 2013, which is the period that we use in the fuzzy 
model to obtain innovation risk results).  
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relationships between innovation risk in the period 2008 to 2013 and sales (or debt) in the period 2008 
to 2013. R-squared of the regressions with instruments are in the range of 41%-42% for CFO innovation 
risk and of 10%-12% for CIO innovation risk. 
Table C.2. Summary of the results of the regression models with lagged independent variables. 
 CFO (i) 
CT dup  
CFO (ii) 
CT no dup  
CIO (iii) 
CT dup 
CIO (iv) 
CT no dup 
Avg Sales -5.64e-09 
 (3.73e-09) 
-6.08e-09*  
(3.31e-09) 
-5.00e-09  
(2.71e-09) 
-5.52e-09**  
(2.44e-09) 
Avg Debt 1.12e-12 
 (1.03e-08) 
1.30e-09 
 (8.84e-09) 
1.16e-08* 
 (7.51e-09) 
1.30e-08* 
 (7.01e-09) 
Constant 0.738***  
(0.024) 
0.735***  
(0.026) 
0.635***  
(0.039) 
0.622*** 
(0.037) 
R-squared 0.414 0.422 0.102 0.125 
No. observations 29 29 29 29 
Note: The dependent variable in each regression is a measure of innovation risk calculated in the period 2008 to 2013: (i) CFO 
with CT duplications, (ii) CFO without CT duplications, (iii) CIO with CT duplications and (iv) CIO without CT duplications. 
The explanatory variables are average sales in the period 2002 to 2007 and average debt in the period 2002 to 2007. In addition, 
*, **, *** indicate significance at the 1, 5 and 10% levels. Bootstrap Standard errors in parentheses. 
We also use ratios as instruments (sales to total assets ratio and debt to total assets ratio in the period 
2002 to 2007) but relationships are not significant at the 10% level. 
As an additional instrument for size, we considered average total assets in the period 2002 to 2007, 
which is significant at the 5% level when the dependent variable is CFO innovation risk but not 
significant at the 10% level when the dependent variable is CIO innovation risk. An alternative way to 
approximate size is market capitalization, in which case we find similar results.  
Furthermore, we also run several OLS regressions with bootstrapping (without trying to infer causality) 
of risk on efficiency (the three efficiency measures in Gascón et al (2017)). In the regressions we mostly 
find a negative relationship between risk and efficiency although it is not always significant at the ten 
percent level. 
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Appendix D. Numerical results. 
Table D.1. Global innovation risk. CFO versus CIO perspective.  
 Chief Financial Officer (CFO) 
OUTPUT31 
Global innovation risk 
CTs without duplications 
Chief Innovation Officer (CIO) 
OUTPUT32 
Global innovation risk 
CTs without duplications 
Chief Financial Officer (CFO) 
OUTPUT31 
Global innovation risk 
CTs with duplications 
Chief Innovation Officer (CIO) 
OUTPUT32 
Global innovation risk 
CTs with duplications 
ABBOTT 68.1% 68.1% 68.2% 70.6% 
ALLERGAN 62.0% 31.9% 62.0% 31.9% 
AMGEM 62.0% 57.0% 66.1% 68.8% 
ASTELLAS 56.8% 49.5% 56.3% 48.6% 
ASTRAZENECA 57.1% 54.5% 58.6% 58.0% 
BAYER 52.1% 55.8% 52.0% 55.5% 
BIOGEN 74.4% 73.9% 74.4% 74.2% 
BRISTOL 71.3% 57.9% 71.0% 57.4% 
CELGENE 72.1% 88.9% 72.1% 88.9% 
EISAI 85.0% 72.9% 84.7% 73.6% 
ELI LILLY 53.4% 51.7% 53.7% 52.3% 
GILEAD 71.0% 48.5% 71.3% 49.0% 
GLAXOSMITHKLINE 39.0% 55.2% 39.1% 57.2% 
H. LUNDBECK 82.2% 70.9% 82.2% 70.3% 
IPSEN 72.2% 52.9% 73.1% 54.6% 
JANSSEN 52.8% 39.6% 56.4% 46.3% 
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MEDICINES COMPANY 88.4% 74.2% 88.0% 75.7% 
MERCK^2 32.4% 45.0% 32.6% 45.8% 
NOVARTIS 47.8% 58.9% 47.8% 59.2% 
NOVONORDISK 70.2% 48.7% 70.7% 49.7% 
ORION 88.8% 72.4% 88.2% 75.0% 
OTSUKA 80.9% 73.2% 80.5% 75.5% 
PFIZER 71.6% 72.6% 71.6% 73.0% 
REGENERON 88.3% 74.5% 88.3% 74.5% 
RICHTER 71.0% 61.8% 74.4% 70.7% 
ROCHE 54.0% 64.2% 54.0% 65.6% 
SANOFI 60.4% 49.8% 60.4% 49.8% 
SHIRE 65.4% 56.9% 66.6% 59.1% 
TAKEDA 63.4% 51.1% 61.9% 48.3% 
TEVA 67.3% 62.3% 67.5% 62.9% 
UCB 76.2% 78.5% 76.0% 79.6% 
Note. The third fuzzy model combines the two previous fuzzy subsystems in order to evaluate global innovation risk in large pharmaceutical laboratories. The first subsystem mainly captures the 
financial side of innovation risk while the second approximates the pipeline side. Based on the risk values obtained in the two previous subsystems, the third subsystem captures the overall 
innovation risk associated with each laboratory. In this third subsystem, we allow for two different perspectives, those of the Chief Financial Officer (CFO) and the Chief Innovation Officer (CIO). 
Results are presented taking into account CTs with and without duplications (see comments in Table A.1 regarding CTs). 
 
